Matthias Meergans

Health Technology Assessment is a valuable tool for chronic patients, including those with Inflammatory Bowel Disease (IBD), as it ensures that decisions about healthcare interventions are based on thorough evaluations of their effectiveness, safety, and cost-effectiveness. For IBD patients, HTA provides a structured way to assess not only the clinical benefits of new treatments but also their impact on patients' quality of life, considering factors such as long-term side effects, ease of use, and the potential for personalized medicine. By involving patients directly in the HTA process, their lived experiences and priorities become central to the decision-making process, making healthcare more patient-centered. This is particularly important for chronic diseases like IBD, where treatments need to be effective over the long term and should align with individual patients’ needs. HTA empowers patients by allowing them to influence the development and approval of therapies that are relevant to their daily lives, ultimately leading to better health outcomes and a more efficient use of healthcare resources. In a broader sense, HTA for chronic conditions emphasizes the importance of sustainable healthcare solutions, balancing innovation with accessibility, and ensuring that the best possible care reaches those who need it the most. Join us at the UEG - United European Gastroenterology week with Alessandro Armuzzi, Yago González Lama, Roberto Saldaña, Néboa Zozaya Gonzalez and Fernando Magro European Federation of Crohn's and Ulcerative Colitis Associations #EFCCA #UnitedWeStand #HTA

16

1 Kommentar

5QQ to... Five Quick Questions to Stefan Walzer: Revolutionizing Healthcare Market Access with AI In this interview, Stefan Walzer, CEO of MArS Market Access & Pricing Strategy GmbH, reveals how AI-driven projects like Q-BO and mAxInsights are transforming healthcare. He shares challenges, strategic insights, and advice for aspiring leaders. Discover the future of healthcare with AI! #HealthcareInnovation #AI #MarketAccess #Leadership #FutureOfHealthcare #Interview

2

1 Kommentar

5QQ to... Five Quick Questions to Stefan Walzer: Revolutionizing Healthcare Market Access with AI In this interview, Stefan Walzer, CEO of MArS Market Access & Pricing Strategy GmbH, reveals how AI-driven projects like Q-BO and mAxInsights are transforming healthcare. He shares challenges, strategic insights, and advice for aspiring leaders. Discover the future of healthcare with AI! #HealthcareInnovation #AI #MarketAccess #Leadership #FutureOfHealthcare #Interview

1

1 Kommentar

🌟 Engage with us at the 58th Diabetes Congress! 🌟 At the 58th Diabetes Kongress, organized by the Deutsche Diabetes Gesellschaft (DDG), our team has a primary mission: to #raiseawareness for metabolic dysfunction-associated steatohepatitis (#MASH). MASH, often referred to as a 'silent disease', presents minimal symptoms, especially in its early stages. As the prevalence of obesity and type 2 diabetes continues to rise—both significant risk factors for MASH—the number of individuals affected by this chronic disease is increasing. Recognizing and diagnosing MASH can be challenging due to its non-specific symptoms, including abdominal and back pain, fatigue, and weakness. For individuals diagnosed with type 2 diabetes and obesity, the FIB-4 index serves as a potent tool for identifying those with a high risk of liver disease. Early diagnosis is crucial, as lifestyle adjustments like diet and exercise can sometimes effectively halt the progression of MASH and, in certain instances, even reverse early-stage liver damage. At Novo Nordisk, we are committed to addressing this issue by leveraging our expertise in obesity and type 2 diabetes. We invite you to engage in this critical dialogue and work together towards a better understanding and management of MASH. #DrivingChange #together #DK2024

136

1 Kommentar

Reflecting on our visit to the recent Saudi Global Health Exhibition, 3 key themes come to mind- Ambition, Speed, and Scale! Firstly, the sheer Ambition was palpable. There was a clear drive to redefine the boundaries of healthcare innovation, spearheading initiatives that not only address current challenges but also anticipate future needs. This ambitious spirit is in perfect harmony with Vision 2030, Saudi Arabia’s roadmap for a vibrant society, thriving economy, and ambitious nation. Secondly, the Speed at which advancements are being integrated into the Saudi healthcare system was equally impressive. Discussions highlighted the rapid adoption of new technologies, accelerated by regulatory support and strategic partnerships. The agility and responsiveness in implementing these changes echoed the Vision 2030 emphasis on efficiency and swift progress. Finally, the Scale of the efforts being undertaken is transformative. From large-scale public health initiatives to widespread deployment of digital health solutions, the impact is vast and far-reaching. The collaborative efforts between government bodies, the private sector, and international partners are set to reshape the healthcare landscape on a massive scale, fulfilling Vision 2030’s promise of significant improvements in patient outcomes and overall system efficiency. Being part of this event provided a profound understanding of the future trajectory of healthcare in Saudi Arabia—a future defined by ambition, speed, and scale, aligned with the goals of Vision 2030! We remain dedicated to supporting our clients navigate the evolving healthcare landscape, to bring the most innovative treatments, medical devices, and technologies to the region for those who need them! Ramy Ghandour, Kashmira Mangavkar, Toby Gosden, Arron Mungul, Laura Jotimliansky, EMC Envision Management Consultancy

17

🌟 rewoso - real world solutions is heading to the #ISPOR in Barcelona! Join us to explore the latest in Real World Evidence and healthcare decision-making. I will be on site between November 17th and 19th to connect with RWE stakeholders and share insights on: - RWE for several indications in #neurology, #rheumatology, #dermatology and #gastroenterology - Digital Health Technology Assessment 📅 Send me a direct message if you would like to have a chat #ISPOREU2024 #ISPOREurope #HEOR #RWE #MarketAccess #HealthEconomics

41

2 Kommentare

#EASD2024 you were electric 😀 Thanks to all participants for their efforts in driving change to defeat diabetes. In my opinion, we have come one step closer to the mission of helping people live longer, healthier lives. My personal highlights? - The presentation of our latest findings regarding the use of the new basal insulins in athletes. - Latest research on the combination of modern long-term insulins with GLP-1 RA. - T2D Care in the digital ear: Presenting digital titration tools for managing type 2 diabetes. You want to stay up to date regarding the latest hot topics in diabetes research and care? Together with our 7 experts we were on site to provide you the latest scientific findings on the therapy of diabetes and its comorbidities. Find all congress highlights on our novoakademie: https://lnkd.in/eTvb9nty #NovoNordisk #Diabetes #EASD2024 #DiabetesAwareness

101

#News: Roche (ROG.S),  on Thursday raised its full-year earnings forecast after exceeding expectations for the first half, driven by strong demand for newer drugs such as #eyemedicine #Vabysmo. The Swiss drugmaker said it expects growth in adjusted earnings in the "high single-digit range", excluding the effect of currency swings and resolution of tax disputes in 2023, up from previous estimates of "mid single-digit" percentage growth. Shares were up 2.4% in morning trading, after earlier rising as much as 4% to a one-year high. First-half adjusted operating profit gained 4% to 11.3 billion Swiss francs ($12.8 billion), the family-controlled drugmaker said on Thursday, beating analysts' consensus estimate of 10.5 billion, based on LSEG data. Read more from Reuters 👇🏼

3

Interesting article and a proposal for a metric to help ensure (more) Pharma R&D productivity. (Probably this is valid also for other industries...). When "senior executive job hopping" results in short-termism, R&D productivity wastage and ultimately less innovative drugs.

8

The European Society of Hypertension Annual Conference is underway in Berlin! Sharing the latest advances in innovation and research at conferences like ESH is crucial to addressing unmet needs and driving progress in hypertension. Resistant and uncontrolled hypertension are significant contributors to cardiovascular and renal complications that affect millions of people worldwide. The limitations of current treatment options mean there is an urgent need for alternatives to improve outcomes. Aldosterone is an important driver of hypertension and cardiorenal outcomes. Read more about aldosterone and the work we are doing to uncover novel approaches to slowing disease progression in hypertension here: https://lnkd.in/eRH38DA3  #ESH2024 #Hypertension #ClinicalInnovation #WhatScienceCanDo 

82

1 Kommentar

Cutaneous metastases (CM) unfortunately develop in many late-stage cancers. Breast cancer is most common with often devasting effects and poor prognosis. A research article just published in JDDG (associated with the German Dermatological Society) describes the epidemiology and therapies for a range of CM including in the “Outlook on Local Procedures” section (page 12) a summary of results from a NanOlogy sponsored trial of SOR007 (topical submicron particle paclitaxel) in CM of breast cancer (Mario Lacouture, M.D., lead investigator). Link to article below.

22

#News: Bayer and Evotec have updated the focus of their strategic collaboration to develop #precisiontreatments for #cardiovasculardiseases (CVDs). Financial terms were not disclosed.   The collaboration aims to identify and validate #noveltargets, with the goal of building a portfolio of precision #cardiologytherapeutics by leveraging #Evotec's disease modelling capabilities using human #inducedpluripotentstemcells (iPSCs). #iPSCs provide unique opportunities to identify new disease mechanisms and pathways for novel treatments. Under the terms of the agreement, both companies will contribute drug targets and a comprehensive set of high-quality technology platforms.   Bayer and Evotec will share responsibilities during the preclinical development of potential clinical candidates. Bayer will be responsible for any subsequent clinical development and commercialization.   “This development takes our long-standing collaboration with Evotec to a new level, and has the added benefit of lessons learned from working together the past 12 years,” said Juergen Eckhardt, M.D., Head of Business Development & Licensing at Bayer’s Pharmaceuticals Division. “We remain committed to develop innovative therapies for patients in need and to tackle the high burden of cardiovascular disease.”
 Read more from Contract Pharma 👇🏼

4

Think the Unthinkable… Federico Faggin’s claim that consciousness is the foundation of the universe turns conventional science on its head. Rather than seeing consciousness as a byproduct of matter, he flips the relationship - an idea as bold as it is reminiscent of great metaphysicians. But as inspiring as this notion is, the question of proof remains. The “Hard Problem of Consciousness” still stands: how do physical processes generate subjective experience? Faggin challenges us to push the boundaries of science. His approach, treating consciousness as the primary substance, sparks a thrilling philosophical debate, even without empirical evidence. But it’s precisely these speculative ideas that drive progress. He reminds us that the greatest discoveries often begin with the courage to think the unthinkable. If consciousness comes before matter, how should we rethink our understanding of the mind and reality? What’s your view on this?

7

6 Kommentare

🌍 Wrapping up an insightful time at ISPOR Europe 2024, here are my top takeaways: 1. EU HTA: A major focus at ISPOR discussing the forthcoming joint clinical assessments across the EU. The anticipation and preparation for its 2025 implementation are crucial, aiming for timely, high-quality assessments that will accelerate patient access and enhance value recognition across the EU. It will be interesting to see any “ripple effects” for countries like Canada. 2. Healthcare Value Expansion: A significant theme, including discussions on broader assessments of healthcare value. Beyond traditional economic determinants, it's essential to consider quality of life improvements, economic contributions, carer burden and efficiencies to the healthcare system. Over the next few years, look out for greater acceptance by HTA bodies and the development of more robust methods. 3. Patient-Centric Research: Numerous sessions emphasized the importance of making research relevant to patient needs and experiences. There were interesting debates if the outcomes currently being measured for regulatory and HTA are what patients really want from innovative medicines. 4. Artificial Intelligence (AI): The potential of AI to revolutionize Health Economics and Outcomes Research (HEOR) was a prominent theme at ISPOR. Defining strategies to integrate AI is crucial, recognizing its capacity to significantly enhance operations and drive innovative healthcare solutions. Regulatory and HTA bodies, as well as pharmaceutical companies are now testing it out in different capacities. These will be standard tools in a several years. #ISPOREurope2024 #HealthcareLearning #PatientCentricity #AI #EUHTA #ValueBasedHealthcare #accesstomedicines

33

4 Kommentare

𝗖𝗼𝗺𝗽𝗮𝗻𝗲𝘀 𝘁𝗼 𝗳𝗼𝗹𝗹𝗼𝘄 - 𝗗𝗿𝘂𝗴 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 The first time I came across the digiM solutions was at this year's DDF Summit in Berlin and had an insightful exchange with Anita Gashi and Joshua Lomeo. The more I learn about digit solutions the more I realize the support they can bring to the drug product development. If you do not yet know digiM, I believe it is of benefit to check and exchange with them. #formulation #drugproduct

7

2 Kommentare

"Give first" is one of the core principles in our company. Anyone who stops by our #PatientsAsPartnersEU booth (# 3), will be able to do that together with us. For any visit, we will be donating to patient scholarships so that more patients can bring their voices to the #clinicalresearch industry. Stop by, say Hi, and learn how you can bring more patient voices 😊 I am posting the picture of my lovely colleagues Rali Vaskova and Daniel Phillips, so that you can reach out and learn more about: - EUPATI's Academy for Patients and how to support - How you can use patient insights to quantify patient burden and predict your trial performance - How to map the patient journey (local Standard of Care) in a few clicks and apply that for better country selection and recruitment strategies. I am also adding their super cool video explaining more about our Initiative. #patientfirst #clinicaltrials #patientengagement #givefirst

22

1 Kommentar

BIO-EUROPE 2024: Panel Discussion with Niklas Hedberg (TLV / co-chair Member State Coordination Group on HTA), Alexander Natz (EUCOPE), Gry Stine Kopperud (Novartis), Sofia Heigis (Oncopeptides) and Fabian Berkemeier (IGES) "Pay The Price": Reimbursement - is there now a single HTA procedure in the European Union? In the European Union (EU), medicines are authorized centrally, but reimbursement is carried out at the national level: the EU member states conduct national assessment procedures for this purpose. Harmonization of these procedures is one of the most important innovations in the regulatory framework for medicines in Europe. From 12 January 2025, a joint clinical assessment will come into force in the EU. This will be introduced gradually, starting with cancer medicines (including orphan oncology drugs) and ATMPs. A whole series of important EU regulations were adopted in 2024. Currently, national regulations are being adapted to the new European procedure in the EU member states. And now, in the fall of 2024, many details regarding the implementation and execution of the new procedure are clarified. This panel will discuss how small and large biopharmaceutical companies need to adapt to the new procedure to reach Europe’s patients quickly and successfully with their innovative therapies: Stockholm, 05 November 2024, 14:00, Exhibit Hall Stage. Niklas Hedberg is the Chief Pharmacist at the Swedish national governmental authority, the Dental and Pharmaceuticals Benefits Agency (TLV).  He is Co-Chair of the Member State Coordination Group, Chair of the Consortium Executive Board for EUnetHTA21 and was the Chair of the EUnetHTA JA 3, Executive Board, 2018 - 2021. Alexander Natz is Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters. Gry Stine Kopperud is Nordic Value & Access Head, Innovative Medicines Novartis. She is skilled in HTA strategy, submission and negotiation, Market Access, RWE and in Nordic tenders. Sofia Heigis, CEO of Oncopeptides - a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. Fabian Berkemeier, General Manager of IGES Institute will moderate the panel. As EU HTA stakeholders, the IGES Institute and IGES Group companies have been closely involved in the discussions and consultations of EUnetHTA21. In addition, the IGES Pharma division is represented by its Basel-based subsidiary HealthEcon as a co-exhibitor at the Swiss joint stand (Booth 53) at Bio Europe. Panel: https://lnkd.in/dcrcPzDR #EUHTA #HTA #BIOEUROPE #IGES Web: https://lnkd.in/dhQGFWxT

2